Novo Nordisk slashing prices for weight-loss and diabetes drugs Ozempic, Wegovy and Rybelsus
Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and Rybelsus, by up to 50 percent beginning next year. Starting on Jan. 1, 2027, the list price for Wegovy, Ozempic and Rybelsus, Novo’s semaglutide products, will be $675 across the board in the U.S. This reduction…
📰 Original Source
Read full article at Thehill →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.